nodes	percent_of_prediction	percent_of_DWPC	metapath
Imatinib—ABCB1—ovarian cancer	0.117	1	CbGaD
Imatinib—ABCG2—Topotecan—ovarian cancer	0.0562	0.155	CbGbCtD
Imatinib—ABCG2—Paclitaxel—ovarian cancer	0.0278	0.0766	CbGbCtD
Imatinib—ABCG2—Carboplatin—ovarian cancer	0.0262	0.0721	CbGbCtD
Imatinib—CYP3A7—Paclitaxel—ovarian cancer	0.0205	0.0566	CbGbCtD
Imatinib—CYP3A7-CYP3A51P—Paclitaxel—ovarian cancer	0.0205	0.0566	CbGbCtD
Imatinib—ABCB1—Topotecan—ovarian cancer	0.0202	0.0558	CbGbCtD
Imatinib—ABCG2—Docetaxel—ovarian cancer	0.0201	0.0554	CbGbCtD
Imatinib—CYP3A5—Paclitaxel—ovarian cancer	0.0154	0.0425	CbGbCtD
Imatinib—ABCG2—Doxorubicin—ovarian cancer	0.015	0.0413	CbGbCtD
Imatinib—CYP3A7—Docetaxel—ovarian cancer	0.0148	0.0409	CbGbCtD
Imatinib—CYP3A7-CYP3A51P—Docetaxel—ovarian cancer	0.0148	0.0409	CbGbCtD
Imatinib—ABCB1—Vinorelbine—ovarian cancer	0.0143	0.0393	CbGbCtD
Imatinib—CYP2D6—Vinorelbine—ovarian cancer	0.0134	0.0371	CbGbCtD
Imatinib—CYP3A4—Topotecan—ovarian cancer	0.0121	0.0334	CbGbCtD
Imatinib—CYP3A5—Docetaxel—ovarian cancer	0.0111	0.0307	CbGbCtD
Imatinib—CYP2C9—Paclitaxel—ovarian cancer	0.0103	0.0285	CbGbCtD
Imatinib—ABCB1—Paclitaxel—ovarian cancer	0.01	0.0276	CbGbCtD
Imatinib—CYP3A4—Vinorelbine—ovarian cancer	0.00855	0.0236	CbGbCtD
Imatinib—ABCB1—Docetaxel—ovarian cancer	0.00725	0.02	CbGbCtD
Imatinib—CYP3A4—Paclitaxel—ovarian cancer	0.00601	0.0166	CbGbCtD
Imatinib—ABCB1—Doxorubicin—ovarian cancer	0.0054	0.0149	CbGbCtD
Imatinib—CYP2D6—Doxorubicin—ovarian cancer	0.00509	0.014	CbGbCtD
Imatinib—CYP3A4—Docetaxel—ovarian cancer	0.00434	0.012	CbGbCtD
Imatinib—CYP3A4—Doxorubicin—ovarian cancer	0.00324	0.00892	CbGbCtD
Imatinib—ABCA3—myometrium—ovarian cancer	0.00243	0.0203	CbGeAlD
Imatinib—NTRK1—decidua—ovarian cancer	0.00228	0.0191	CbGeAlD
Imatinib—DDR1—myometrium—ovarian cancer	0.00224	0.0187	CbGeAlD
Imatinib—ABCA3—decidua—ovarian cancer	0.0018	0.0151	CbGeAlD
Imatinib—DDR1—uterine cervix—ovarian cancer	0.00175	0.0146	CbGeAlD
Imatinib—ABCA3—endometrium—ovarian cancer	0.00171	0.0143	CbGeAlD
Imatinib—DDR1—decidua—ovarian cancer	0.00166	0.0139	CbGeAlD
Imatinib—HIPK4—gonad—ovarian cancer	0.0016	0.0134	CbGeAlD
Imatinib—DDR1—endometrium—ovarian cancer	0.00158	0.0132	CbGeAlD
Imatinib—DDR1—uterus—ovarian cancer	0.00145	0.0122	CbGeAlD
Imatinib—NTRK1—testis—ovarian cancer	0.00145	0.0121	CbGeAlD
Imatinib—HIPK4—female reproductive system—ovarian cancer	0.00143	0.012	CbGeAlD
Imatinib—PIP4K2C—myometrium—ovarian cancer	0.00138	0.0116	CbGeAlD
Imatinib—CA3—myometrium—ovarian cancer	0.00132	0.0111	CbGeAlD
Imatinib—ABCA3—female gonad—ovarian cancer	0.00129	0.0108	CbGeAlD
Imatinib—ABCA3—vagina—ovarian cancer	0.00128	0.0107	CbGeAlD
Imatinib—DDR1—female gonad—ovarian cancer	0.00119	0.00995	CbGeAlD
Imatinib—DDR1—vagina—ovarian cancer	0.00118	0.00989	CbGeAlD
Imatinib—PTGS1—oviduct—ovarian cancer	0.00116	0.0097	CbGeAlD
Imatinib—HIPK4—testis—ovarian cancer	0.00116	0.00967	CbGeAlD
Imatinib—ABCA3—testis—ovarian cancer	0.00114	0.00956	CbGeAlD
Imatinib—PIP4K2C—uterine cervix—ovarian cancer	0.00108	0.00901	CbGeAlD
Imatinib—DDR1—testis—ovarian cancer	0.00106	0.00882	CbGeAlD
Imatinib—CA3—uterine cervix—ovarian cancer	0.00103	0.0086	CbGeAlD
Imatinib—PIP4K2C—decidua—ovarian cancer	0.00103	0.00858	CbGeAlD
Imatinib—NQO2—myometrium—ovarian cancer	0.00102	0.0085	CbGeAlD
Imatinib—PDGFRA—embryo—ovarian cancer	0.000976	0.00815	CbGeAlD
Imatinib—PIP4K2C—endometrium—ovarian cancer	0.000974	0.00815	CbGeAlD
Imatinib—LCK—uterine cervix—ovarian cancer	0.000956	0.00799	CbGeAlD
Imatinib—LCK—decidua—ovarian cancer	0.000911	0.00762	CbGeAlD
Imatinib—PIP4K2C—gonad—ovarian cancer	0.000904	0.00756	CbGeAlD
Imatinib—CSF1R—myometrium—ovarian cancer	0.000893	0.00746	CbGeAlD
Imatinib—CSF1R—embryo—ovarian cancer	0.000859	0.00718	CbGeAlD
Imatinib—CA3—uterus—ovarian cancer	0.000857	0.00717	CbGeAlD
Imatinib—ABCA3—lymph node—ovarian cancer	0.000829	0.00693	CbGeAlD
Imatinib—SLC47A1—myometrium—ovarian cancer	0.000816	0.00682	CbGeAlD
Imatinib—KIT—myometrium—ovarian cancer	0.000811	0.00678	CbGeAlD
Imatinib—PIP4K2C—female reproductive system—ovarian cancer	0.000807	0.00675	CbGeAlD
Imatinib—LCK—uterus—ovarian cancer	0.000797	0.00666	CbGeAlD
Imatinib—PDGFRB—myometrium—ovarian cancer	0.000792	0.00662	CbGeAlD
Imatinib—NQO2—uterine cervix—ovarian cancer	0.000791	0.00661	CbGeAlD
Imatinib—KIT—embryo—ovarian cancer	0.00078	0.00652	CbGeAlD
Imatinib—ABL2—female gonad—ovarian cancer	0.000776	0.00649	CbGeAlD
Imatinib—ABL2—vagina—ovarian cancer	0.000772	0.00645	CbGeAlD
Imatinib—DDR1—lymph node—ovarian cancer	0.000765	0.0064	CbGeAlD
Imatinib—PIP4K2C—bone marrow—ovarian cancer	0.000762	0.00637	CbGeAlD
Imatinib—PDGFRB—embryo—ovarian cancer	0.000762	0.00637	CbGeAlD
Imatinib—NQO2—decidua—ovarian cancer	0.000754	0.0063	CbGeAlD
Imatinib—PDGFRA—decidua—ovarian cancer	0.000752	0.00629	CbGeAlD
Imatinib—CA9—female reproductive system—ovarian cancer	0.000738	0.00617	CbGeAlD
Imatinib—PIP4K2C—female gonad—ovarian cancer	0.000735	0.00614	CbGeAlD
Imatinib—PIP4K2C—vagina—ovarian cancer	0.00073	0.0061	CbGeAlD
Imatinib—CA3—bone marrow—ovarian cancer	0.000728	0.00608	CbGeAlD
Imatinib—NQO2—endometrium—ovarian cancer	0.000716	0.00598	CbGeAlD
Imatinib—ABL1—myometrium—ovarian cancer	0.000706	0.0059	CbGeAlD
Imatinib—CA3—vagina—ovarian cancer	0.000697	0.00583	CbGeAlD
Imatinib—CSF1R—uterine cervix—ovarian cancer	0.000695	0.00581	CbGeAlD
Imatinib—ABL2—testis—ovarian cancer	0.000689	0.00576	CbGeAlD
Imatinib—ABL1—embryo—ovarian cancer	0.000679	0.00568	CbGeAlD
Imatinib—LCK—bone marrow—ovarian cancer	0.000676	0.00565	CbGeAlD
Imatinib—PDGFRA—gonad—ovarian cancer	0.000662	0.00554	CbGeAlD
Imatinib—CSF1R—decidua—ovarian cancer	0.000662	0.00553	CbGeAlD
Imatinib—NQO2—uterus—ovarian cancer	0.000659	0.00551	CbGeAlD
Imatinib—PDGFRA—uterus—ovarian cancer	0.000658	0.0055	CbGeAlD
Imatinib—LCK—female gonad—ovarian cancer	0.000652	0.00545	CbGeAlD
Imatinib—PIP4K2C—testis—ovarian cancer	0.000651	0.00545	CbGeAlD
Imatinib—LCK—vagina—ovarian cancer	0.000648	0.00542	CbGeAlD
Imatinib—KIT—epithelium—ovarian cancer	0.000636	0.00532	CbGeAlD
Imatinib—SLC47A1—uterine cervix—ovarian cancer	0.000635	0.0053	CbGeAlD
Imatinib—KIT—uterine cervix—ovarian cancer	0.000631	0.00527	CbGeAlD
Imatinib—CSF1R—endometrium—ovarian cancer	0.000628	0.00525	CbGeAlD
Imatinib—CA3—testis—ovarian cancer	0.000622	0.0052	CbGeAlD
Imatinib—PDGFRB—epithelium—ovarian cancer	0.000622	0.0052	CbGeAlD
Imatinib—PDGFRB—uterine cervix—ovarian cancer	0.000616	0.00515	CbGeAlD
Imatinib—SLC47A1—decidua—ovarian cancer	0.000605	0.00505	CbGeAlD
Imatinib—KIT—decidua—ovarian cancer	0.000601	0.00503	CbGeAlD
Imatinib—CA9—testis—ovarian cancer	0.000595	0.00498	CbGeAlD
Imatinib—NQO2—female reproductive system—ovarian cancer	0.000593	0.00496	CbGeAlD
Imatinib—PDGFRA—female reproductive system—ovarian cancer	0.000591	0.00494	CbGeAlD
Imatinib—PDGFRB—decidua—ovarian cancer	0.000587	0.00491	CbGeAlD
Imatinib—CSF1R—gonad—ovarian cancer	0.000583	0.00487	CbGeAlD
Imatinib—CSF1R—uterus—ovarian cancer	0.000579	0.00484	CbGeAlD
Imatinib—LCK—testis—ovarian cancer	0.000578	0.00483	CbGeAlD
Imatinib—SLC47A1—endometrium—ovarian cancer	0.000574	0.0048	CbGeAlD
Imatinib—KIT—endometrium—ovarian cancer	0.000571	0.00477	CbGeAlD
Imatinib—ABL1—Daunorubicin—Epirubicin—ovarian cancer	0.00057	0.173	CbGdCrCtD
Imatinib—ABL1—Doxorubicin—Epirubicin—ovarian cancer	0.00057	0.173	CbGdCrCtD
Imatinib—ABL1—Idarubicin—Epirubicin—ovarian cancer	0.00057	0.173	CbGdCrCtD
Imatinib—NQO2—bone marrow—ovarian cancer	0.00056	0.00468	CbGeAlD
Imatinib—PDGFRB—endometrium—ovarian cancer	0.000557	0.00466	CbGeAlD
Imatinib—ABL1—uterine cervix—ovarian cancer	0.000549	0.00459	CbGeAlD
Imatinib—CA12—female reproductive system—ovarian cancer	0.000546	0.00456	CbGeAlD
Imatinib—NQO2—female gonad—ovarian cancer	0.000539	0.00451	CbGeAlD
Imatinib—PDGFRA—female gonad—ovarian cancer	0.000538	0.0045	CbGeAlD
Imatinib—NQO2—vagina—ovarian cancer	0.000536	0.00448	CbGeAlD
Imatinib—PDGFRA—vagina—ovarian cancer	0.000535	0.00447	CbGeAlD
Imatinib—SLC47A1—gonad—ovarian cancer	0.000532	0.00445	CbGeAlD
Imatinib—KIT—gonad—ovarian cancer	0.000529	0.00442	CbGeAlD
Imatinib—SLC47A1—uterus—ovarian cancer	0.000529	0.00442	CbGeAlD
Imatinib—ABL1—Epirubicin—Doxorubicin—ovarian cancer	0.000527	0.16	CbGdCrCtD
Imatinib—ABL1—Idarubicin—Doxorubicin—ovarian cancer	0.000527	0.16	CbGdCrCtD
Imatinib—ABL1—Daunorubicin—Doxorubicin—ovarian cancer	0.000527	0.16	CbGdCrCtD
Imatinib—KIT—uterus—ovarian cancer	0.000526	0.0044	CbGeAlD
Imatinib—ABL1—decidua—ovarian cancer	0.000523	0.00437	CbGeAlD
Imatinib—ORM1—endometrium—ovarian cancer	0.000523	0.00437	CbGeAlD
Imatinib—CSF1R—female reproductive system—ovarian cancer	0.000521	0.00435	CbGeAlD
Imatinib—PDGFRB—gonad—ovarian cancer	0.000517	0.00432	CbGeAlD
Imatinib—PDGFRB—uterus—ovarian cancer	0.000514	0.00429	CbGeAlD
Imatinib—ABL2—lymph node—ovarian cancer	0.000499	0.00417	CbGeAlD
Imatinib—ABL1—endometrium—ovarian cancer	0.000497	0.00415	CbGeAlD
Imatinib—CSF1R—bone marrow—ovarian cancer	0.000492	0.00411	CbGeAlD
Imatinib—NQO2—testis—ovarian cancer	0.000478	0.004	CbGeAlD
Imatinib—PDGFRA—testis—ovarian cancer	0.000477	0.00399	CbGeAlD
Imatinib—SLC47A1—female reproductive system—ovarian cancer	0.000475	0.00397	CbGeAlD
Imatinib—CSF1R—female gonad—ovarian cancer	0.000474	0.00396	CbGeAlD
Imatinib—KIT—female reproductive system—ovarian cancer	0.000473	0.00395	CbGeAlD
Imatinib—PIP4K2C—lymph node—ovarian cancer	0.000472	0.00395	CbGeAlD
Imatinib—CSF1R—vagina—ovarian cancer	0.000471	0.00394	CbGeAlD
Imatinib—CA2—embryo—ovarian cancer	0.000462	0.00386	CbGeAlD
Imatinib—PDGFRB—female reproductive system—ovarian cancer	0.000462	0.00386	CbGeAlD
Imatinib—ABL1—gonad—ovarian cancer	0.000461	0.00385	CbGeAlD
Imatinib—ABL1—uterus—ovarian cancer	0.000458	0.00383	CbGeAlD
Imatinib—CA3—lymph node—ovarian cancer	0.000451	0.00377	CbGeAlD
Imatinib—KIT—bone marrow—ovarian cancer	0.000446	0.00373	CbGeAlD
Imatinib—ABCG2—myometrium—ovarian cancer	0.000445	0.00372	CbGeAlD
Imatinib—PDGFRB—bone marrow—ovarian cancer	0.000436	0.00364	CbGeAlD
Imatinib—ORM1—female reproductive system—ovarian cancer	0.000433	0.00362	CbGeAlD
Imatinib—SLC47A1—female gonad—ovarian cancer	0.000433	0.00362	CbGeAlD
Imatinib—CA1—female reproductive system—ovarian cancer	0.000432	0.00361	CbGeAlD
Imatinib—KIT—female gonad—ovarian cancer	0.00043	0.0036	CbGeAlD
Imatinib—SLC47A1—vagina—ovarian cancer	0.00043	0.00359	CbGeAlD
Imatinib—KIT—vagina—ovarian cancer	0.000428	0.00357	CbGeAlD
Imatinib—CSF1R—testis—ovarian cancer	0.00042	0.00351	CbGeAlD
Imatinib—PDGFRB—female gonad—ovarian cancer	0.00042	0.00351	CbGeAlD
Imatinib—LCK—lymph node—ovarian cancer	0.000419	0.0035	CbGeAlD
Imatinib—PDGFRB—vagina—ovarian cancer	0.000418	0.00349	CbGeAlD
Imatinib—ABL1—female reproductive system—ovarian cancer	0.000412	0.00344	CbGeAlD
Imatinib—ORM1—bone marrow—ovarian cancer	0.000409	0.00342	CbGeAlD
Imatinib—CA1—bone marrow—ovarian cancer	0.000408	0.00341	CbGeAlD
Imatinib—ABL1—bone marrow—ovarian cancer	0.000389	0.00325	CbGeAlD
Imatinib—SLC47A1—testis—ovarian cancer	0.000384	0.00321	CbGeAlD
Imatinib—KIT—testis—ovarian cancer	0.000382	0.00319	CbGeAlD
Imatinib—CA2—epithelium—ovarian cancer	0.000377	0.00315	CbGeAlD
Imatinib—ABL1—female gonad—ovarian cancer	0.000374	0.00313	CbGeAlD
Imatinib—PDGFRB—testis—ovarian cancer	0.000373	0.00312	CbGeAlD
Imatinib—ABL1—vagina—ovarian cancer	0.000372	0.00311	CbGeAlD
Imatinib—SLC22A1—vagina—ovarian cancer	0.000359	0.003	CbGeAlD
Imatinib—CA2—decidua—ovarian cancer	0.000356	0.00298	CbGeAlD
Imatinib—NQO2—lymph node—ovarian cancer	0.000347	0.0029	CbGeAlD
Imatinib—ABCG2—uterine cervix—ovarian cancer	0.000346	0.0029	CbGeAlD
Imatinib—PDGFRA—lymph node—ovarian cancer	0.000346	0.00289	CbGeAlD
Imatinib—ABL1—testis—ovarian cancer	0.000332	0.00278	CbGeAlD
Imatinib—ABCG2—decidua—ovarian cancer	0.00033	0.00276	CbGeAlD
Imatinib—CYP3A5—uterine cervix—ovarian cancer	0.000322	0.00269	CbGeAlD
Imatinib—ABCG2—endometrium—ovarian cancer	0.000313	0.00262	CbGeAlD
Imatinib—ALB—testis—ovarian cancer	0.000307	0.00256	CbGeAlD
Imatinib—CSF1R—lymph node—ovarian cancer	0.000305	0.00255	CbGeAlD
Imatinib—PTGS1—epithelium—ovarian cancer	0.000291	0.00244	CbGeAlD
Imatinib—PTGS1—uterine cervix—ovarian cancer	0.000289	0.00241	CbGeAlD
Imatinib—ABCG2—uterus—ovarian cancer	0.000289	0.00241	CbGeAlD
Imatinib—CA2—female reproductive system—ovarian cancer	0.00028	0.00234	CbGeAlD
Imatinib—SLC47A1—lymph node—ovarian cancer	0.000278	0.00233	CbGeAlD
Imatinib—CYP2C19—vagina—ovarian cancer	0.000277	0.00231	CbGeAlD
Imatinib—KIT—lymph node—ovarian cancer	0.000277	0.00231	CbGeAlD
Imatinib—PDGFRB—lymph node—ovarian cancer	0.00027	0.00226	CbGeAlD
Imatinib—CA2—bone marrow—ovarian cancer	0.000265	0.00221	CbGeAlD
Imatinib—PTGS1—endometrium—ovarian cancer	0.000261	0.00218	CbGeAlD
Imatinib—CA2—female gonad—ovarian cancer	0.000255	0.00213	CbGeAlD
Imatinib—CA2—vagina—ovarian cancer	0.000253	0.00212	CbGeAlD
Imatinib—ORM1—lymph node—ovarian cancer	0.000253	0.00212	CbGeAlD
Imatinib—CA1—lymph node—ovarian cancer	0.000253	0.00211	CbGeAlD
Imatinib—ABCG2—bone marrow—ovarian cancer	0.000245	0.00205	CbGeAlD
Imatinib—Ponatinib—ABCB1—ovarian cancer	0.000244	0.576	CrCbGaD
Imatinib—PTGS1—uterus—ovarian cancer	0.000241	0.00201	CbGeAlD
Imatinib—ABL1—lymph node—ovarian cancer	0.000241	0.00201	CbGeAlD
Imatinib—CYP2C9—female reproductive system—ovarian cancer	0.000237	0.00198	CbGeAlD
Imatinib—ABCG2—female gonad—ovarian cancer	0.000236	0.00197	CbGeAlD
Imatinib—ABCG2—vagina—ovarian cancer	0.000235	0.00196	CbGeAlD
Imatinib—CA2—testis—ovarian cancer	0.000226	0.00189	CbGeAlD
Imatinib—ALB—lymph node—ovarian cancer	0.000222	0.00186	CbGeAlD
Imatinib—ABCB1—myometrium—ovarian cancer	0.000219	0.00183	CbGeAlD
Imatinib—CYP3A5—female gonad—ovarian cancer	0.000219	0.00183	CbGeAlD
Imatinib—CYP3A5—vagina—ovarian cancer	0.000218	0.00182	CbGeAlD
Imatinib—PTGS1—female reproductive system—ovarian cancer	0.000216	0.00181	CbGeAlD
Imatinib—ABCB1—embryo—ovarian cancer	0.000211	0.00176	CbGeAlD
Imatinib—ABCG2—testis—ovarian cancer	0.000209	0.00175	CbGeAlD
Imatinib—PTGS1—female gonad—ovarian cancer	0.000197	0.00165	CbGeAlD
Imatinib—PTGS1—vagina—ovarian cancer	0.000196	0.00164	CbGeAlD
Imatinib—CYP3A4—female reproductive system—ovarian cancer	0.000181	0.00151	CbGeAlD
Imatinib—Nilotinib—ABCB1—ovarian cancer	0.00018	0.425	CrCbGaD
Imatinib—CYP2D6—female reproductive system—ovarian cancer	0.000178	0.00149	CbGeAlD
Imatinib—PTGS1—testis—ovarian cancer	0.000175	0.00146	CbGeAlD
Imatinib—ABCB1—epithelium—ovarian cancer	0.000172	0.00144	CbGeAlD
Imatinib—ABCB1—uterine cervix—ovarian cancer	0.000171	0.00143	CbGeAlD
Imatinib—CA2—lymph node—ovarian cancer	0.000164	0.00137	CbGeAlD
Imatinib—ABCB1—decidua—ovarian cancer	0.000163	0.00136	CbGeAlD
Imatinib—CYP2D6—female gonad—ovarian cancer	0.000162	0.00135	CbGeAlD
Imatinib—ABCB1—endometrium—ovarian cancer	0.000154	0.00129	CbGeAlD
Imatinib—ABCG2—lymph node—ovarian cancer	0.000152	0.00127	CbGeAlD
Imatinib—CYP2D6—testis—ovarian cancer	0.000144	0.0012	CbGeAlD
Imatinib—ABCB1—gonad—ovarian cancer	0.000143	0.0012	CbGeAlD
Imatinib—ABCB1—uterus—ovarian cancer	0.000142	0.00119	CbGeAlD
Imatinib—ABCB1—female reproductive system—ovarian cancer	0.000128	0.00107	CbGeAlD
Imatinib—PTGS1—lymph node—ovarian cancer	0.000127	0.00106	CbGeAlD
Imatinib—ABCB1—bone marrow—ovarian cancer	0.000121	0.00101	CbGeAlD
Imatinib—ABCB1—female gonad—ovarian cancer	0.000116	0.000973	CbGeAlD
Imatinib—ABCB1—vagina—ovarian cancer	0.000116	0.000968	CbGeAlD
Imatinib—ABCB1—testis—ovarian cancer	0.000103	0.000863	CbGeAlD
Imatinib—ABCB1—lymph node—ovarian cancer	7.49e-05	0.000626	CbGeAlD
Imatinib—Sweating—Epirubicin—ovarian cancer	7.45e-05	0.000316	CcSEcCtD
Imatinib—Pollakiuria—Doxorubicin—ovarian cancer	7.45e-05	0.000316	CcSEcCtD
Imatinib—Pain—Paclitaxel—ovarian cancer	7.41e-05	0.000314	CcSEcCtD
Imatinib—Constipation—Paclitaxel—ovarian cancer	7.41e-05	0.000314	CcSEcCtD
Imatinib—Haematuria—Epirubicin—ovarian cancer	7.41e-05	0.000314	CcSEcCtD
Imatinib—Confusional state—Docetaxel—ovarian cancer	7.41e-05	0.000314	CcSEcCtD
Imatinib—Photosensitivity reaction—Doxorubicin—ovarian cancer	7.36e-05	0.000312	CcSEcCtD
Imatinib—Hepatobiliary disease—Epirubicin—ovarian cancer	7.35e-05	0.000311	CcSEcCtD
Imatinib—Anaphylactic shock—Docetaxel—ovarian cancer	7.35e-05	0.000311	CcSEcCtD
Imatinib—Oedema—Docetaxel—ovarian cancer	7.35e-05	0.000311	CcSEcCtD
Imatinib—Weight increased—Doxorubicin—ovarian cancer	7.34e-05	0.000311	CcSEcCtD
Imatinib—Epistaxis—Epirubicin—ovarian cancer	7.33e-05	0.000311	CcSEcCtD
Imatinib—Infection—Docetaxel—ovarian cancer	7.3e-05	0.000309	CcSEcCtD
Imatinib—Weight decreased—Doxorubicin—ovarian cancer	7.29e-05	0.000309	CcSEcCtD
Imatinib—Sinusitis—Epirubicin—ovarian cancer	7.29e-05	0.000309	CcSEcCtD
Imatinib—Hyperglycaemia—Doxorubicin—ovarian cancer	7.27e-05	0.000308	CcSEcCtD
Imatinib—Agranulocytosis—Epirubicin—ovarian cancer	7.25e-05	0.000307	CcSEcCtD
Imatinib—Pneumonia—Doxorubicin—ovarian cancer	7.23e-05	0.000307	CcSEcCtD
Imatinib—Shock—Docetaxel—ovarian cancer	7.23e-05	0.000306	CcSEcCtD
Imatinib—Nervous system disorder—Docetaxel—ovarian cancer	7.2e-05	0.000305	CcSEcCtD
Imatinib—Thrombocytopenia—Docetaxel—ovarian cancer	7.19e-05	0.000305	CcSEcCtD
Imatinib—Infestation NOS—Doxorubicin—ovarian cancer	7.19e-05	0.000305	CcSEcCtD
Imatinib—Infestation—Doxorubicin—ovarian cancer	7.19e-05	0.000305	CcSEcCtD
Imatinib—Tachycardia—Docetaxel—ovarian cancer	7.17e-05	0.000304	CcSEcCtD
Imatinib—Feeling abnormal—Paclitaxel—ovarian cancer	7.14e-05	0.000303	CcSEcCtD
Imatinib—Skin disorder—Docetaxel—ovarian cancer	7.14e-05	0.000302	CcSEcCtD
Imatinib—Stevens-Johnson syndrome—Doxorubicin—ovarian cancer	7.13e-05	0.000302	CcSEcCtD
Imatinib—Gastrointestinal pain—Paclitaxel—ovarian cancer	7.09e-05	0.0003	CcSEcCtD
Imatinib—Renal failure—Doxorubicin—ovarian cancer	7.07e-05	0.0003	CcSEcCtD
Imatinib—Neuropathy peripheral—Doxorubicin—ovarian cancer	7.05e-05	0.000299	CcSEcCtD
Imatinib—Haemoglobin—Epirubicin—ovarian cancer	7.01e-05	0.000297	CcSEcCtD
Imatinib—Jaundice—Doxorubicin—ovarian cancer	7.01e-05	0.000297	CcSEcCtD
Imatinib—Stomatitis—Doxorubicin—ovarian cancer	7.01e-05	0.000297	CcSEcCtD
Imatinib—Anorexia—Docetaxel—ovarian cancer	7e-05	0.000297	CcSEcCtD
Imatinib—Rhinitis—Epirubicin—ovarian cancer	6.99e-05	0.000296	CcSEcCtD
Imatinib—Urinary tract infection—Doxorubicin—ovarian cancer	6.99e-05	0.000296	CcSEcCtD
Imatinib—Conjunctivitis—Doxorubicin—ovarian cancer	6.99e-05	0.000296	CcSEcCtD
Imatinib—Hepatitis—Epirubicin—ovarian cancer	6.97e-05	0.000296	CcSEcCtD
Imatinib—Haemorrhage—Epirubicin—ovarian cancer	6.97e-05	0.000296	CcSEcCtD
Imatinib—Hypoaesthesia—Epirubicin—ovarian cancer	6.94e-05	0.000294	CcSEcCtD
Imatinib—Pharyngitis—Epirubicin—ovarian cancer	6.92e-05	0.000293	CcSEcCtD
Imatinib—Sweating—Doxorubicin—ovarian cancer	6.89e-05	0.000292	CcSEcCtD
Imatinib—Urinary tract disorder—Epirubicin—ovarian cancer	6.89e-05	0.000292	CcSEcCtD
Imatinib—Urticaria—Paclitaxel—ovarian cancer	6.89e-05	0.000292	CcSEcCtD
Imatinib—Oedema peripheral—Epirubicin—ovarian cancer	6.87e-05	0.000291	CcSEcCtD
Imatinib—Hypotension—Docetaxel—ovarian cancer	6.87e-05	0.000291	CcSEcCtD
Imatinib—Haematuria—Doxorubicin—ovarian cancer	6.85e-05	0.000291	CcSEcCtD
Imatinib—Connective tissue disorder—Epirubicin—ovarian cancer	6.85e-05	0.000291	CcSEcCtD
Imatinib—Abdominal pain—Paclitaxel—ovarian cancer	6.85e-05	0.00029	CcSEcCtD
Imatinib—Body temperature increased—Paclitaxel—ovarian cancer	6.85e-05	0.00029	CcSEcCtD
Imatinib—Urethral disorder—Epirubicin—ovarian cancer	6.84e-05	0.00029	CcSEcCtD
Imatinib—Hepatobiliary disease—Doxorubicin—ovarian cancer	6.8e-05	0.000288	CcSEcCtD
Imatinib—Epistaxis—Doxorubicin—ovarian cancer	6.78e-05	0.000287	CcSEcCtD
Imatinib—Sinusitis—Doxorubicin—ovarian cancer	6.74e-05	0.000286	CcSEcCtD
Imatinib—Agranulocytosis—Doxorubicin—ovarian cancer	6.71e-05	0.000284	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Docetaxel—ovarian cancer	6.69e-05	0.000284	CcSEcCtD
Imatinib—Insomnia—Docetaxel—ovarian cancer	6.64e-05	0.000282	CcSEcCtD
Imatinib—Paraesthesia—Docetaxel—ovarian cancer	6.6e-05	0.00028	CcSEcCtD
Imatinib—Erythema multiforme—Epirubicin—ovarian cancer	6.59e-05	0.00028	CcSEcCtD
Imatinib—Dyspnoea—Docetaxel—ovarian cancer	6.55e-05	0.000278	CcSEcCtD
Imatinib—Somnolence—Docetaxel—ovarian cancer	6.53e-05	0.000277	CcSEcCtD
Imatinib—Eye disorder—Epirubicin—ovarian cancer	6.52e-05	0.000276	CcSEcCtD
Imatinib—Tinnitus—Epirubicin—ovarian cancer	6.5e-05	0.000276	CcSEcCtD
Imatinib—Haemoglobin—Doxorubicin—ovarian cancer	6.49e-05	0.000275	CcSEcCtD
Imatinib—Cardiac disorder—Epirubicin—ovarian cancer	6.47e-05	0.000274	CcSEcCtD
Imatinib—Flushing—Epirubicin—ovarian cancer	6.47e-05	0.000274	CcSEcCtD
Imatinib—Rhinitis—Doxorubicin—ovarian cancer	6.47e-05	0.000274	CcSEcCtD
Imatinib—Dyspepsia—Docetaxel—ovarian cancer	6.47e-05	0.000274	CcSEcCtD
Imatinib—Haemorrhage—Doxorubicin—ovarian cancer	6.45e-05	0.000274	CcSEcCtD
Imatinib—Hepatitis—Doxorubicin—ovarian cancer	6.45e-05	0.000274	CcSEcCtD
Imatinib—Hypoaesthesia—Doxorubicin—ovarian cancer	6.42e-05	0.000272	CcSEcCtD
Imatinib—Pharyngitis—Doxorubicin—ovarian cancer	6.41e-05	0.000272	CcSEcCtD
Imatinib—Decreased appetite—Docetaxel—ovarian cancer	6.39e-05	0.000271	CcSEcCtD
Imatinib—Hypersensitivity—Paclitaxel—ovarian cancer	6.39e-05	0.000271	CcSEcCtD
Imatinib—Urinary tract disorder—Doxorubicin—ovarian cancer	6.37e-05	0.00027	CcSEcCtD
Imatinib—Oedema peripheral—Doxorubicin—ovarian cancer	6.36e-05	0.000269	CcSEcCtD
Imatinib—Gastrointestinal disorder—Docetaxel—ovarian cancer	6.34e-05	0.000269	CcSEcCtD
Imatinib—Connective tissue disorder—Doxorubicin—ovarian cancer	6.34e-05	0.000269	CcSEcCtD
Imatinib—Fatigue—Docetaxel—ovarian cancer	6.33e-05	0.000268	CcSEcCtD
Imatinib—Angiopathy—Epirubicin—ovarian cancer	6.33e-05	0.000268	CcSEcCtD
Imatinib—Urethral disorder—Doxorubicin—ovarian cancer	6.33e-05	0.000268	CcSEcCtD
Imatinib—Immune system disorder—Epirubicin—ovarian cancer	6.3e-05	0.000267	CcSEcCtD
Imatinib—Mediastinal disorder—Epirubicin—ovarian cancer	6.29e-05	0.000266	CcSEcCtD
Imatinib—Pain—Docetaxel—ovarian cancer	6.28e-05	0.000266	CcSEcCtD
Imatinib—Constipation—Docetaxel—ovarian cancer	6.28e-05	0.000266	CcSEcCtD
Imatinib—Chills—Epirubicin—ovarian cancer	6.26e-05	0.000265	CcSEcCtD
Imatinib—Arrhythmia—Epirubicin—ovarian cancer	6.23e-05	0.000264	CcSEcCtD
Imatinib—Asthenia—Paclitaxel—ovarian cancer	6.22e-05	0.000264	CcSEcCtD
Imatinib—Alopecia—Epirubicin—ovarian cancer	6.16e-05	0.000261	CcSEcCtD
Imatinib—Pruritus—Paclitaxel—ovarian cancer	6.13e-05	0.00026	CcSEcCtD
Imatinib—Mental disorder—Epirubicin—ovarian cancer	6.11e-05	0.000259	CcSEcCtD
Imatinib—Erythema multiforme—Doxorubicin—ovarian cancer	6.1e-05	0.000259	CcSEcCtD
Imatinib—Malnutrition—Epirubicin—ovarian cancer	6.07e-05	0.000257	CcSEcCtD
Imatinib—Erythema—Epirubicin—ovarian cancer	6.07e-05	0.000257	CcSEcCtD
Imatinib—Feeling abnormal—Docetaxel—ovarian cancer	6.05e-05	0.000257	CcSEcCtD
Imatinib—Eye disorder—Doxorubicin—ovarian cancer	6.03e-05	0.000256	CcSEcCtD
Imatinib—Tinnitus—Doxorubicin—ovarian cancer	6.02e-05	0.000255	CcSEcCtD
Imatinib—Gastrointestinal pain—Docetaxel—ovarian cancer	6.01e-05	0.000255	CcSEcCtD
Imatinib—Flushing—Doxorubicin—ovarian cancer	5.99e-05	0.000254	CcSEcCtD
Imatinib—Cardiac disorder—Doxorubicin—ovarian cancer	5.99e-05	0.000254	CcSEcCtD
Imatinib—Flatulence—Epirubicin—ovarian cancer	5.98e-05	0.000254	CcSEcCtD
Imatinib—Dysgeusia—Epirubicin—ovarian cancer	5.95e-05	0.000252	CcSEcCtD
Imatinib—Diarrhoea—Paclitaxel—ovarian cancer	5.93e-05	0.000251	CcSEcCtD
Imatinib—Back pain—Epirubicin—ovarian cancer	5.87e-05	0.000249	CcSEcCtD
Imatinib—Angiopathy—Doxorubicin—ovarian cancer	5.86e-05	0.000248	CcSEcCtD
Imatinib—Muscle spasms—Epirubicin—ovarian cancer	5.84e-05	0.000247	CcSEcCtD
Imatinib—Immune system disorder—Doxorubicin—ovarian cancer	5.83e-05	0.000247	CcSEcCtD
Imatinib—Mediastinal disorder—Doxorubicin—ovarian cancer	5.82e-05	0.000247	CcSEcCtD
Imatinib—Body temperature increased—Docetaxel—ovarian cancer	5.81e-05	0.000246	CcSEcCtD
Imatinib—Abdominal pain—Docetaxel—ovarian cancer	5.81e-05	0.000246	CcSEcCtD
Imatinib—Chills—Doxorubicin—ovarian cancer	5.79e-05	0.000245	CcSEcCtD
Imatinib—Arrhythmia—Doxorubicin—ovarian cancer	5.77e-05	0.000244	CcSEcCtD
Imatinib—Dizziness—Paclitaxel—ovarian cancer	5.73e-05	0.000243	CcSEcCtD
Imatinib—Vision blurred—Epirubicin—ovarian cancer	5.72e-05	0.000243	CcSEcCtD
Imatinib—Alopecia—Doxorubicin—ovarian cancer	5.7e-05	0.000242	CcSEcCtD
Imatinib—Mental disorder—Doxorubicin—ovarian cancer	5.65e-05	0.00024	CcSEcCtD
Imatinib—Ill-defined disorder—Epirubicin—ovarian cancer	5.63e-05	0.000239	CcSEcCtD
Imatinib—Malnutrition—Doxorubicin—ovarian cancer	5.62e-05	0.000238	CcSEcCtD
Imatinib—Erythema—Doxorubicin—ovarian cancer	5.62e-05	0.000238	CcSEcCtD
Imatinib—Anaemia—Epirubicin—ovarian cancer	5.61e-05	0.000238	CcSEcCtD
Imatinib—Flatulence—Doxorubicin—ovarian cancer	5.54e-05	0.000235	CcSEcCtD
Imatinib—Vomiting—Paclitaxel—ovarian cancer	5.51e-05	0.000234	CcSEcCtD
Imatinib—Dysgeusia—Doxorubicin—ovarian cancer	5.5e-05	0.000233	CcSEcCtD
Imatinib—Malaise—Epirubicin—ovarian cancer	5.48e-05	0.000232	CcSEcCtD
Imatinib—Rash—Paclitaxel—ovarian cancer	5.47e-05	0.000232	CcSEcCtD
Imatinib—Dermatitis—Paclitaxel—ovarian cancer	5.46e-05	0.000231	CcSEcCtD
Imatinib—Vertigo—Epirubicin—ovarian cancer	5.46e-05	0.000231	CcSEcCtD
Imatinib—Syncope—Epirubicin—ovarian cancer	5.45e-05	0.000231	CcSEcCtD
Imatinib—Leukopenia—Epirubicin—ovarian cancer	5.43e-05	0.00023	CcSEcCtD
Imatinib—Back pain—Doxorubicin—ovarian cancer	5.43e-05	0.00023	CcSEcCtD
Imatinib—Headache—Paclitaxel—ovarian cancer	5.43e-05	0.00023	CcSEcCtD
Imatinib—Hypersensitivity—Docetaxel—ovarian cancer	5.41e-05	0.000229	CcSEcCtD
Imatinib—Muscle spasms—Doxorubicin—ovarian cancer	5.4e-05	0.000229	CcSEcCtD
Imatinib—Palpitations—Epirubicin—ovarian cancer	5.37e-05	0.000227	CcSEcCtD
Imatinib—Loss of consciousness—Epirubicin—ovarian cancer	5.34e-05	0.000226	CcSEcCtD
Imatinib—Cough—Epirubicin—ovarian cancer	5.3e-05	0.000225	CcSEcCtD
Imatinib—Vision blurred—Doxorubicin—ovarian cancer	5.29e-05	0.000224	CcSEcCtD
Imatinib—Asthenia—Docetaxel—ovarian cancer	5.27e-05	0.000223	CcSEcCtD
Imatinib—Convulsion—Epirubicin—ovarian cancer	5.26e-05	0.000223	CcSEcCtD
Imatinib—Hypertension—Epirubicin—ovarian cancer	5.24e-05	0.000222	CcSEcCtD
Imatinib—Ill-defined disorder—Doxorubicin—ovarian cancer	5.21e-05	0.000221	CcSEcCtD
Imatinib—Pruritus—Docetaxel—ovarian cancer	5.2e-05	0.00022	CcSEcCtD
Imatinib—Anaemia—Doxorubicin—ovarian cancer	5.19e-05	0.00022	CcSEcCtD
Imatinib—Arthralgia—Epirubicin—ovarian cancer	5.17e-05	0.000219	CcSEcCtD
Imatinib—Chest pain—Epirubicin—ovarian cancer	5.17e-05	0.000219	CcSEcCtD
Imatinib—Myalgia—Epirubicin—ovarian cancer	5.17e-05	0.000219	CcSEcCtD
Imatinib—Anxiety—Epirubicin—ovarian cancer	5.15e-05	0.000218	CcSEcCtD
Imatinib—Nausea—Paclitaxel—ovarian cancer	5.15e-05	0.000218	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	5.13e-05	0.000218	CcSEcCtD
Imatinib—Discomfort—Epirubicin—ovarian cancer	5.11e-05	0.000216	CcSEcCtD
Imatinib—Malaise—Doxorubicin—ovarian cancer	5.07e-05	0.000215	CcSEcCtD
Imatinib—Dry mouth—Epirubicin—ovarian cancer	5.06e-05	0.000214	CcSEcCtD
Imatinib—Vertigo—Doxorubicin—ovarian cancer	5.05e-05	0.000214	CcSEcCtD
Imatinib—Syncope—Doxorubicin—ovarian cancer	5.04e-05	0.000214	CcSEcCtD
Imatinib—Leukopenia—Doxorubicin—ovarian cancer	5.03e-05	0.000213	CcSEcCtD
Imatinib—Diarrhoea—Docetaxel—ovarian cancer	5.03e-05	0.000213	CcSEcCtD
Imatinib—Confusional state—Epirubicin—ovarian cancer	5e-05	0.000212	CcSEcCtD
Imatinib—Palpitations—Doxorubicin—ovarian cancer	4.96e-05	0.00021	CcSEcCtD
Imatinib—Anaphylactic shock—Epirubicin—ovarian cancer	4.96e-05	0.00021	CcSEcCtD
Imatinib—Oedema—Epirubicin—ovarian cancer	4.96e-05	0.00021	CcSEcCtD
Imatinib—Loss of consciousness—Doxorubicin—ovarian cancer	4.94e-05	0.000209	CcSEcCtD
Imatinib—Infection—Epirubicin—ovarian cancer	4.92e-05	0.000209	CcSEcCtD
Imatinib—Cough—Doxorubicin—ovarian cancer	4.9e-05	0.000208	CcSEcCtD
Imatinib—Shock—Epirubicin—ovarian cancer	4.88e-05	0.000207	CcSEcCtD
Imatinib—Convulsion—Doxorubicin—ovarian cancer	4.87e-05	0.000206	CcSEcCtD
Imatinib—Nervous system disorder—Epirubicin—ovarian cancer	4.86e-05	0.000206	CcSEcCtD
Imatinib—Dizziness—Docetaxel—ovarian cancer	4.86e-05	0.000206	CcSEcCtD
Imatinib—Thrombocytopenia—Epirubicin—ovarian cancer	4.85e-05	0.000206	CcSEcCtD
Imatinib—Hypertension—Doxorubicin—ovarian cancer	4.85e-05	0.000206	CcSEcCtD
Imatinib—Tachycardia—Epirubicin—ovarian cancer	4.84e-05	0.000205	CcSEcCtD
Imatinib—Skin disorder—Epirubicin—ovarian cancer	4.81e-05	0.000204	CcSEcCtD
Imatinib—Hyperhidrosis—Epirubicin—ovarian cancer	4.79e-05	0.000203	CcSEcCtD
Imatinib—Chest pain—Doxorubicin—ovarian cancer	4.78e-05	0.000203	CcSEcCtD
Imatinib—Arthralgia—Doxorubicin—ovarian cancer	4.78e-05	0.000203	CcSEcCtD
Imatinib—Myalgia—Doxorubicin—ovarian cancer	4.78e-05	0.000203	CcSEcCtD
Imatinib—Anxiety—Doxorubicin—ovarian cancer	4.77e-05	0.000202	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	4.75e-05	0.000201	CcSEcCtD
Imatinib—Discomfort—Doxorubicin—ovarian cancer	4.73e-05	0.0002	CcSEcCtD
Imatinib—Anorexia—Epirubicin—ovarian cancer	4.72e-05	0.0002	CcSEcCtD
Imatinib—Dry mouth—Doxorubicin—ovarian cancer	4.68e-05	0.000198	CcSEcCtD
Imatinib—Vomiting—Docetaxel—ovarian cancer	4.67e-05	0.000198	CcSEcCtD
Imatinib—Rash—Docetaxel—ovarian cancer	4.63e-05	0.000196	CcSEcCtD
Imatinib—Hypotension—Epirubicin—ovarian cancer	4.63e-05	0.000196	CcSEcCtD
Imatinib—Dermatitis—Docetaxel—ovarian cancer	4.63e-05	0.000196	CcSEcCtD
Imatinib—Confusional state—Doxorubicin—ovarian cancer	4.62e-05	0.000196	CcSEcCtD
Imatinib—Headache—Docetaxel—ovarian cancer	4.6e-05	0.000195	CcSEcCtD
Imatinib—Anaphylactic shock—Doxorubicin—ovarian cancer	4.59e-05	0.000194	CcSEcCtD
Imatinib—Oedema—Doxorubicin—ovarian cancer	4.59e-05	0.000194	CcSEcCtD
Imatinib—Infection—Doxorubicin—ovarian cancer	4.56e-05	0.000193	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Epirubicin—ovarian cancer	4.51e-05	0.000191	CcSEcCtD
Imatinib—Shock—Doxorubicin—ovarian cancer	4.51e-05	0.000191	CcSEcCtD
Imatinib—Nervous system disorder—Doxorubicin—ovarian cancer	4.5e-05	0.000191	CcSEcCtD
Imatinib—Thrombocytopenia—Doxorubicin—ovarian cancer	4.49e-05	0.00019	CcSEcCtD
Imatinib—Insomnia—Epirubicin—ovarian cancer	4.48e-05	0.00019	CcSEcCtD
Imatinib—Tachycardia—Doxorubicin—ovarian cancer	4.47e-05	0.00019	CcSEcCtD
Imatinib—Skin disorder—Doxorubicin—ovarian cancer	4.45e-05	0.000189	CcSEcCtD
Imatinib—Paraesthesia—Epirubicin—ovarian cancer	4.45e-05	0.000189	CcSEcCtD
Imatinib—Hyperhidrosis—Doxorubicin—ovarian cancer	4.43e-05	0.000188	CcSEcCtD
Imatinib—Dyspnoea—Epirubicin—ovarian cancer	4.42e-05	0.000187	CcSEcCtD
Imatinib—Somnolence—Epirubicin—ovarian cancer	4.41e-05	0.000187	CcSEcCtD
Imatinib—Anorexia—Doxorubicin—ovarian cancer	4.37e-05	0.000185	CcSEcCtD
Imatinib—Nausea—Docetaxel—ovarian cancer	4.36e-05	0.000185	CcSEcCtD
Imatinib—Dyspepsia—Epirubicin—ovarian cancer	4.36e-05	0.000185	CcSEcCtD
Imatinib—Decreased appetite—Epirubicin—ovarian cancer	4.31e-05	0.000183	CcSEcCtD
Imatinib—Hypotension—Doxorubicin—ovarian cancer	4.28e-05	0.000182	CcSEcCtD
Imatinib—Gastrointestinal disorder—Epirubicin—ovarian cancer	4.28e-05	0.000181	CcSEcCtD
Imatinib—Fatigue—Epirubicin—ovarian cancer	4.27e-05	0.000181	CcSEcCtD
Imatinib—Constipation—Epirubicin—ovarian cancer	4.24e-05	0.00018	CcSEcCtD
Imatinib—Pain—Epirubicin—ovarian cancer	4.24e-05	0.00018	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	4.18e-05	0.000177	CcSEcCtD
Imatinib—Insomnia—Doxorubicin—ovarian cancer	4.15e-05	0.000176	CcSEcCtD
Imatinib—Paraesthesia—Doxorubicin—ovarian cancer	4.12e-05	0.000175	CcSEcCtD
Imatinib—Dyspnoea—Doxorubicin—ovarian cancer	4.09e-05	0.000173	CcSEcCtD
Imatinib—Feeling abnormal—Epirubicin—ovarian cancer	4.08e-05	0.000173	CcSEcCtD
Imatinib—Somnolence—Doxorubicin—ovarian cancer	4.08e-05	0.000173	CcSEcCtD
Imatinib—Gastrointestinal pain—Epirubicin—ovarian cancer	4.05e-05	0.000172	CcSEcCtD
Imatinib—Dyspepsia—Doxorubicin—ovarian cancer	4.04e-05	0.000171	CcSEcCtD
Imatinib—Decreased appetite—Doxorubicin—ovarian cancer	3.99e-05	0.000169	CcSEcCtD
Imatinib—Gastrointestinal disorder—Doxorubicin—ovarian cancer	3.96e-05	0.000168	CcSEcCtD
Imatinib—Fatigue—Doxorubicin—ovarian cancer	3.95e-05	0.000168	CcSEcCtD
Imatinib—Urticaria—Epirubicin—ovarian cancer	3.94e-05	0.000167	CcSEcCtD
Imatinib—Pain—Doxorubicin—ovarian cancer	3.92e-05	0.000166	CcSEcCtD
Imatinib—Constipation—Doxorubicin—ovarian cancer	3.92e-05	0.000166	CcSEcCtD
Imatinib—Abdominal pain—Epirubicin—ovarian cancer	3.92e-05	0.000166	CcSEcCtD
Imatinib—Body temperature increased—Epirubicin—ovarian cancer	3.92e-05	0.000166	CcSEcCtD
Imatinib—Feeling abnormal—Doxorubicin—ovarian cancer	3.78e-05	0.00016	CcSEcCtD
Imatinib—Gastrointestinal pain—Doxorubicin—ovarian cancer	3.75e-05	0.000159	CcSEcCtD
Imatinib—Hypersensitivity—Epirubicin—ovarian cancer	3.65e-05	0.000155	CcSEcCtD
Imatinib—Urticaria—Doxorubicin—ovarian cancer	3.64e-05	0.000154	CcSEcCtD
Imatinib—Abdominal pain—Doxorubicin—ovarian cancer	3.62e-05	0.000154	CcSEcCtD
Imatinib—Body temperature increased—Doxorubicin—ovarian cancer	3.62e-05	0.000154	CcSEcCtD
Imatinib—Asthenia—Epirubicin—ovarian cancer	3.56e-05	0.000151	CcSEcCtD
Imatinib—Pruritus—Epirubicin—ovarian cancer	3.51e-05	0.000149	CcSEcCtD
Imatinib—Diarrhoea—Epirubicin—ovarian cancer	3.39e-05	0.000144	CcSEcCtD
Imatinib—Hypersensitivity—Doxorubicin—ovarian cancer	3.38e-05	0.000143	CcSEcCtD
Imatinib—Asthenia—Doxorubicin—ovarian cancer	3.29e-05	0.000139	CcSEcCtD
Imatinib—Dizziness—Epirubicin—ovarian cancer	3.28e-05	0.000139	CcSEcCtD
Imatinib—Pruritus—Doxorubicin—ovarian cancer	3.24e-05	0.000138	CcSEcCtD
Imatinib—Vomiting—Epirubicin—ovarian cancer	3.15e-05	0.000134	CcSEcCtD
Imatinib—Diarrhoea—Doxorubicin—ovarian cancer	3.14e-05	0.000133	CcSEcCtD
Imatinib—Rash—Epirubicin—ovarian cancer	3.12e-05	0.000132	CcSEcCtD
Imatinib—Dermatitis—Epirubicin—ovarian cancer	3.12e-05	0.000132	CcSEcCtD
Imatinib—Headache—Epirubicin—ovarian cancer	3.1e-05	0.000132	CcSEcCtD
Imatinib—Dizziness—Doxorubicin—ovarian cancer	3.03e-05	0.000129	CcSEcCtD
Imatinib—Nausea—Epirubicin—ovarian cancer	2.94e-05	0.000125	CcSEcCtD
Imatinib—Vomiting—Doxorubicin—ovarian cancer	2.92e-05	0.000124	CcSEcCtD
Imatinib—Rash—Doxorubicin—ovarian cancer	2.89e-05	0.000123	CcSEcCtD
Imatinib—Dermatitis—Doxorubicin—ovarian cancer	2.89e-05	0.000122	CcSEcCtD
Imatinib—Headache—Doxorubicin—ovarian cancer	2.87e-05	0.000122	CcSEcCtD
Imatinib—Nausea—Doxorubicin—ovarian cancer	2.72e-05	0.000115	CcSEcCtD
Imatinib—PDGFRB—Disease—MAPK1—ovarian cancer	4.02e-06	2.49e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—EGFR—ovarian cancer	4.02e-06	2.49e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—KRAS—ovarian cancer	4e-06	2.48e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—MTOR—ovarian cancer	4e-06	2.48e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—PIK3CB—ovarian cancer	4e-06	2.48e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	4e-06	2.48e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—MAPK1—ovarian cancer	3.98e-06	2.47e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—CCND1—ovarian cancer	3.98e-06	2.47e-05	CbGpPWpGaD
Imatinib—LCK—Disease—PTEN—ovarian cancer	3.96e-06	2.46e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—CTNNB1—ovarian cancer	3.94e-06	2.44e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—PIK3CD—ovarian cancer	3.94e-06	2.44e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PPP2R1A—ovarian cancer	3.92e-06	2.43e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—IL6—ovarian cancer	3.92e-06	2.43e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—PIK3CA—ovarian cancer	3.91e-06	2.42e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—FASN—ovarian cancer	3.88e-06	2.4e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—HRAS—ovarian cancer	3.88e-06	2.4e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—PIK3CA—ovarian cancer	3.87e-06	2.4e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—MMP9—ovarian cancer	3.86e-06	2.39e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CXCL8—ovarian cancer	3.85e-06	2.38e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—STAT3—ovarian cancer	3.84e-06	2.38e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—PTEN—ovarian cancer	3.84e-06	2.38e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—NRAS—ovarian cancer	3.83e-06	2.37e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—CAV1—ovarian cancer	3.82e-06	2.37e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—SLC5A5—ovarian cancer	3.81e-06	2.36e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—KRAS—ovarian cancer	3.79e-06	2.35e-05	CbGpPWpGaD
Imatinib—KIT—Disease—HRAS—ovarian cancer	3.78e-06	2.34e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—TP53—ovarian cancer	3.78e-06	2.34e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—PIK3CA—ovarian cancer	3.78e-06	2.34e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—KRAS—ovarian cancer	3.76e-06	2.33e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CDKN1B—ovarian cancer	3.76e-06	2.33e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—ABCB1—ovarian cancer	3.73e-06	2.31e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—PIK3CB—ovarian cancer	3.72e-06	2.31e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—IL6—ovarian cancer	3.71e-06	2.3e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PPP2R1A—ovarian cancer	3.7e-06	2.29e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—PIK3CB—ovarian cancer	3.69e-06	2.29e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—PIK3CD—ovarian cancer	3.69e-06	2.28e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—SLC2A1—ovarian cancer	3.68e-06	2.28e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—PIK3CB—ovarian cancer	3.68e-06	2.28e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CASP3—ovarian cancer	3.68e-06	2.28e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—PIK3CA—ovarian cancer	3.68e-06	2.28e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—IL2—ovarian cancer	3.68e-06	2.28e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—YAP1—ovarian cancer	3.67e-06	2.28e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—MAPK3—ovarian cancer	3.67e-06	2.27e-05	CbGpPWpGaD
Imatinib—CA9—Metabolism—AKT1—ovarian cancer	3.67e-06	2.27e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—TYMS—ovarian cancer	3.67e-06	2.27e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PPP2R1A—ovarian cancer	3.67e-06	2.27e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—VEGFA—ovarian cancer	3.66e-06	2.27e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	3.65e-06	2.26e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—STAT3—ovarian cancer	3.63e-06	2.25e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—NRAS—ovarian cancer	3.62e-06	2.24e-05	CbGpPWpGaD
Imatinib—KIT—Disease—IL6—ovarian cancer	3.62e-06	2.24e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—AKT1—ovarian cancer	3.62e-06	2.24e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—HRAS—ovarian cancer	3.61e-06	2.24e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	3.61e-06	2.24e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CCND1—ovarian cancer	3.58e-06	2.22e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—HRAS—ovarian cancer	3.58e-06	2.22e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—TYMS—ovarian cancer	3.58e-06	2.22e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—PIK3CB—ovarian cancer	3.58e-06	2.22e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CTNNB1—ovarian cancer	3.55e-06	2.2e-05	CbGpPWpGaD
Imatinib—LCK—Disease—STAT3—ovarian cancer	3.55e-06	2.2e-05	CbGpPWpGaD
Imatinib—LCK—Disease—NRAS—ovarian cancer	3.54e-06	2.19e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—CYP1B1—ovarian cancer	3.53e-06	2.19e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—HRAS—ovarian cancer	3.49e-06	2.16e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—MAPK1—ovarian cancer	3.49e-06	2.16e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—EGFR—ovarian cancer	3.49e-06	2.16e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—PIK3CA—ovarian cancer	3.49e-06	2.16e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PIK3CG—ovarian cancer	3.48e-06	2.16e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—MMP9—ovarian cancer	3.48e-06	2.16e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—VEGFA—ovarian cancer	3.47e-06	2.15e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—MAPK3—ovarian cancer	3.47e-06	2.15e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—PTEN—ovarian cancer	3.46e-06	2.14e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—IL6—ovarian cancer	3.46e-06	2.14e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—PIK3CA—ovarian cancer	3.45e-06	2.14e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—STAT3—ovarian cancer	3.43e-06	2.13e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—PIK3CB—ovarian cancer	3.43e-06	2.13e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—ABCB1—ovarian cancer	3.43e-06	2.13e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—NRAS—ovarian cancer	3.43e-06	2.12e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—IL6—ovarian cancer	3.43e-06	2.12e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—AKT1—ovarian cancer	3.42e-06	2.12e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—ABCB1—ovarian cancer	3.4e-06	2.11e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—HRAS—ovarian cancer	3.4e-06	2.11e-05	CbGpPWpGaD
Imatinib—LCK—Disease—MAPK3—ovarian cancer	3.39e-06	2.1e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—TYMS—ovarian cancer	3.37e-06	2.09e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—MYC—ovarian cancer	3.37e-06	2.09e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—TYMS—ovarian cancer	3.34e-06	2.07e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—IL6—ovarian cancer	3.34e-06	2.07e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—TP53—ovarian cancer	3.34e-06	2.07e-05	CbGpPWpGaD
Imatinib—KIT—Disease—AKT1—ovarian cancer	3.34e-06	2.07e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—MAPK1—ovarian cancer	3.3e-06	2.04e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—EGFR—ovarian cancer	3.3e-06	2.04e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—KRAS—ovarian cancer	3.3e-06	2.04e-05	CbGpPWpGaD
Imatinib—LCK—Disease—MYC—ovarian cancer	3.29e-06	2.04e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—CAV1—ovarian cancer	3.29e-06	2.04e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—MAPK3—ovarian cancer	3.28e-06	2.03e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—IL6—ovarian cancer	3.26e-06	2.02e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—ERBB2—ovarian cancer	3.26e-06	2.02e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—HRAS—ovarian cancer	3.22e-06	2e-05	CbGpPWpGaD
Imatinib—LCK—Disease—MAPK1—ovarian cancer	3.22e-06	2e-05	CbGpPWpGaD
Imatinib—LCK—Disease—EGFR—ovarian cancer	3.22e-06	2e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—PTEN—ovarian cancer	3.22e-06	1.99e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MTOR—ovarian cancer	3.21e-06	1.99e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—PIK3CB—ovarian cancer	3.21e-06	1.99e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—HRAS—ovarian cancer	3.2e-06	1.98e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—MYC—ovarian cancer	3.19e-06	1.98e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—AKT1—ovarian cancer	3.19e-06	1.98e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—PTEN—ovarian cancer	3.19e-06	1.98e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—PTEN—ovarian cancer	3.18e-06	1.97e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—AKT1—ovarian cancer	3.16e-06	1.96e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	3.14e-06	1.95e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PPP2R1A—ovarian cancer	3.13e-06	1.94e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—VEGFA—ovarian cancer	3.13e-06	1.94e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—MAPK1—ovarian cancer	3.12e-06	1.93e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—EGFR—ovarian cancer	3.12e-06	1.93e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	3.12e-06	1.93e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—KRAS—ovarian cancer	3.12e-06	1.93e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—STAT3—ovarian cancer	3.09e-06	1.92e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—PTEN—ovarian cancer	3.09e-06	1.92e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CXCL8—ovarian cancer	3.09e-06	1.91e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—NRAS—ovarian cancer	3.09e-06	1.91e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—IL6—ovarian cancer	3.09e-06	1.91e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—AKT1—ovarian cancer	3.08e-06	1.91e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PIK3CD—ovarian cancer	3.06e-06	1.9e-05	CbGpPWpGaD
Imatinib—LCK—Disease—KRAS—ovarian cancer	3.04e-06	1.89e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—PIK3CA—ovarian cancer	3.03e-06	1.88e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CDKN1B—ovarian cancer	3.02e-06	1.87e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—AKT1—ovarian cancer	3.01e-06	1.86e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—PIK3CG—ovarian cancer	3e-06	1.86e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—FASN—ovarian cancer	2.99e-06	1.85e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—PTEN—ovarian cancer	2.97e-06	1.84e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—MAPK3—ovarian cancer	2.96e-06	1.83e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CASP3—ovarian cancer	2.96e-06	1.83e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—CAV1—ovarian cancer	2.95e-06	1.83e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—IL2—ovarian cancer	2.95e-06	1.83e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—KRAS—ovarian cancer	2.95e-06	1.83e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—SLC5A5—ovarian cancer	2.94e-06	1.82e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—ABCB1—ovarian cancer	2.91e-06	1.8e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—CAV1—ovarian cancer	2.88e-06	1.79e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CCND1—ovarian cancer	2.88e-06	1.78e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—MYC—ovarian cancer	2.88e-06	1.78e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—PIK3CA—ovarian cancer	2.86e-06	1.77e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—TYMS—ovarian cancer	2.86e-06	1.77e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CTNNB1—ovarian cancer	2.85e-06	1.77e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—AKT1—ovarian cancer	2.85e-06	1.76e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—SLC2A1—ovarian cancer	2.84e-06	1.76e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.82e-06	1.75e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—AKT1—ovarian cancer	2.82e-06	1.75e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—MAPK1—ovarian cancer	2.81e-06	1.74e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—EGFR—ovarian cancer	2.81e-06	1.74e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—HRAS—ovarian cancer	2.8e-06	1.74e-05	CbGpPWpGaD
Imatinib—LCK—Disease—PIK3CA—ovarian cancer	2.8e-06	1.73e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MMP9—ovarian cancer	2.79e-06	1.73e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—PTEN—ovarian cancer	2.78e-06	1.72e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—TP53—ovarian cancer	2.77e-06	1.72e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CYP1B1—ovarian cancer	2.73e-06	1.69e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—CAV1—ovarian cancer	2.72e-06	1.68e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—PIK3CA—ovarian cancer	2.71e-06	1.68e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—CAV1—ovarian cancer	2.69e-06	1.67e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PIK3CG—ovarian cancer	2.69e-06	1.67e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—IL6—ovarian cancer	2.68e-06	1.66e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PIK3CB—ovarian cancer	2.67e-06	1.65e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—KRAS—ovarian cancer	2.66e-06	1.65e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—HRAS—ovarian cancer	2.65e-06	1.64e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—PIK3CD—ovarian cancer	2.64e-06	1.63e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PIK3CG—ovarian cancer	2.63e-06	1.63e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—TP53—ovarian cancer	2.62e-06	1.62e-05	CbGpPWpGaD
Imatinib—LCK—Disease—HRAS—ovarian cancer	2.59e-06	1.6e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.57e-06	1.59e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—IL6—ovarian cancer	2.53e-06	1.57e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—VEGFA—ovarian cancer	2.51e-06	1.55e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—HRAS—ovarian cancer	2.51e-06	1.55e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—STAT3—ovarian cancer	2.48e-06	1.54e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—NRAS—ovarian cancer	2.48e-06	1.54e-05	CbGpPWpGaD
Imatinib—LCK—Disease—IL6—ovarian cancer	2.48e-06	1.54e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PIK3CG—ovarian cancer	2.48e-06	1.53e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—AKT1—ovarian cancer	2.47e-06	1.53e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PIK3CG—ovarian cancer	2.45e-06	1.52e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—PIK3CA—ovarian cancer	2.44e-06	1.51e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	2.42e-06	1.5e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—IL6—ovarian cancer	2.4e-06	1.49e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MAPK3—ovarian cancer	2.37e-06	1.47e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PIK3CD—ovarian cancer	2.37e-06	1.47e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—TP53—ovarian cancer	2.36e-06	1.46e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—AKT1—ovarian cancer	2.34e-06	1.45e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PIK3CD—ovarian cancer	2.31e-06	1.43e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MYC—ovarian cancer	2.31e-06	1.43e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PTEN—ovarian cancer	2.3e-06	1.43e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—CAV1—ovarian cancer	2.3e-06	1.43e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—PIK3CB—ovarian cancer	2.3e-06	1.42e-05	CbGpPWpGaD
Imatinib—LCK—Disease—AKT1—ovarian cancer	2.29e-06	1.42e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—PIK3CA—ovarian cancer	2.27e-06	1.41e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—HRAS—ovarian cancer	2.26e-06	1.4e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MAPK1—ovarian cancer	2.26e-06	1.4e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—EGFR—ovarian cancer	2.26e-06	1.4e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—PIK3CA—ovarian cancer	2.25e-06	1.39e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—PIK3CA—ovarian cancer	2.25e-06	1.39e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—ABCB1—ovarian cancer	2.24e-06	1.39e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—AKT1—ovarian cancer	2.21e-06	1.37e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—TYMS—ovarian cancer	2.2e-06	1.37e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.2e-06	1.36e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—PIK3CA—ovarian cancer	2.18e-06	1.35e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PIK3CD—ovarian cancer	2.18e-06	1.35e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—IL6—ovarian cancer	2.16e-06	1.34e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PIK3CD—ovarian cancer	2.16e-06	1.34e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—KRAS—ovarian cancer	2.13e-06	1.32e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PIK3CG—ovarian cancer	2.1e-06	1.3e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—PIK3CA—ovarian cancer	2.09e-06	1.3e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PIK3CB—ovarian cancer	2.06e-06	1.28e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PIK3CB—ovarian cancer	2.01e-06	1.25e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—AKT1—ovarian cancer	1.99e-06	1.24e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—PTEN—ovarian cancer	1.98e-06	1.23e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—PIK3CA—ovarian cancer	1.96e-06	1.21e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PIK3CB—ovarian cancer	1.9e-06	1.18e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—TP53—ovarian cancer	1.89e-06	1.17e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PIK3CB—ovarian cancer	1.88e-06	1.17e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—AKT1—ovarian cancer	1.85e-06	1.15e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PIK3CD—ovarian cancer	1.84e-06	1.14e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—AKT1—ovarian cancer	1.84e-06	1.14e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—AKT1—ovarian cancer	1.83e-06	1.14e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—HRAS—ovarian cancer	1.81e-06	1.12e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PTEN—ovarian cancer	1.78e-06	1.1e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—AKT1—ovarian cancer	1.78e-06	1.1e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CAV1—ovarian cancer	1.78e-06	1.1e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PTEN—ovarian cancer	1.74e-06	1.08e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—IL6—ovarian cancer	1.73e-06	1.07e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—AKT1—ovarian cancer	1.71e-06	1.06e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PTEN—ovarian cancer	1.64e-06	1.02e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PIK3CA—ovarian cancer	1.63e-06	1.01e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PTEN—ovarian cancer	1.62e-06	1.01e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PIK3CG—ovarian cancer	1.62e-06	1e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PIK3CB—ovarian cancer	1.61e-06	9.96e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—AKT1—ovarian cancer	1.6e-06	9.92e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PIK3CD—ovarian cancer	1.42e-06	8.82e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—PIK3CA—ovarian cancer	1.4e-06	8.68e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PTEN—ovarian cancer	1.39e-06	8.6e-06	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—AKT1—ovarian cancer	1.33e-06	8.23e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PIK3CA—ovarian cancer	1.26e-06	7.79e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PIK3CB—ovarian cancer	1.24e-06	7.68e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PIK3CA—ovarian cancer	1.23e-06	7.6e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PIK3CA—ovarian cancer	1.16e-06	7.17e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PIK3CA—ovarian cancer	1.15e-06	7.1e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—AKT1—ovarian cancer	1.14e-06	7.09e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PTEN—ovarian cancer	1.07e-06	6.64e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—AKT1—ovarian cancer	1.03e-06	6.36e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—AKT1—ovarian cancer	1e-06	6.21e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PIK3CA—ovarian cancer	9.79e-07	6.07e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—AKT1—ovarian cancer	9.44e-07	5.85e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—AKT1—ovarian cancer	9.36e-07	5.8e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—AKT1—ovarian cancer	8e-07	4.96e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PIK3CA—ovarian cancer	7.56e-07	4.68e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—AKT1—ovarian cancer	6.18e-07	3.83e-06	CbGpPWpGaD
